Please be patient! It may take up to ONE minute to load all the Engines.
Problems? Please contact our support.
Paroxysmal nocturnal hemoglobinuria (PNH)
DefinitionParoxysmal nocturnal hemoglobinuria is a rare, acquired disorder of red blood cells in which an abnormal cell surface molecule leads to premature destruction of the cells. This destruction is intermittent (paroxysmal).
Causes, incidence, and risk factors
PNH is caused by a defect in the formation of a red cell surface protein anchor, called GP1. As a result of the lack of this surface protein anchor, a number of surface proteins are unable to remain tethered to the cell surface. This includes the protein CD55, or Decay Accelerating Factor (DAF).
The result of the loss of these cell surface proteins is an enhanced sensitivity to complement-mediated cell destruction. ( Complement is a substance produced by the immune system.) The disease can affect people of any age.
Red blood cell, white blood cell, and platelet counts may be low. Urine may be intermittently red or brown, signifying the breakdown of red blood cells with release of hemoglobin into the circulation and then the urine.
Blood clots may form in some people. The disease may arise in relation to aplastic anemia , and may progress to acute myelogenous leukemia . Risk factors, except for prior aplastic anemia, are not known.
Signs and tests
Steroids may be effective in suppressing hemolysis. Blood transfusions may be required. Anticoagulation therapy may also be required to prevent clot formation.
Bone marrow transplantation can cure this disease.
Expectations (prognosis)The outcome is variable, with most people surviving approximately 10 years following diagnosis. In rare cases, the abnormal cells may decrease over time. Death can be caused by complications of blood clot formation (thrombosis).
Calling your health care provider
Call your health care provider if you find blood in your urine, if symptoms worsen or do not improve with treatment or if new symptoms develop.
PreventionThere is no known way to prevent this disorder.
Update Date: 10/13/2003Corey Cutler, M.D., M.P.H., F.R.C.P.C, Department of Medical Oncology, Dana-Farber Cancer Institute; Instructor in Medicine, Harvard University, Boston, MA. Review provided by VeriMed Healthcare Network.
Last updated: Tue, 06 Jan 2009 00:20:03 GMT